In vitro inhibitory effect of SR 27417, a potent platelet-activating factor (PAF) receptor antagonist, on the PAF-induced bovine platelet aggregation | Veterinary Research, a journal on Animal Infection

Free Access

Issue		Vet. Res. Volume 31, Number 2, March-April 2000


Page(s)		267 - 272
DOI		https://doi.org/10.1051/vetres:2000115
How to cite this article		Vet. Res. (2000) 267-272

References

1: Argiolas L., Fabi F., Del Basso P., Mechanisms of pulmonary vasoconstriction and bronchoconstriction produced by PAF in the guinea-pig: role of platelets and cyclo-oxygenase metabolites, Br. J. Pharmacol. 114 (1995) 203-209.
2: Bastos da Silva M., Herion F., Raskinet R., David J-L., Gustin P., Dessy C., Lekeux P., Inhibition of PAF-induced platelet aggregation by WEB 2086 in vitro, an antagonist to the receptor for platelet-activating factor, in bovine, J. Vet. Med. A 43 (1996) 399-413.
3: Bastos da Silva M., Gustin P., Herion F., Raskinet R. David J.-L., Gougnard T., Plomteux G., Desmecht D., Lekeux P., The effect of intravenous administration of WEB 2086 on PAF-induced platelet aggregation in health Friesian calves, Vet. Res. Commun. 21 (1997) 521-531.
4: Bastos da Silva M., Dessy C., David J.-L., Lekeux P., Morphological alterations of blood platelets induced by platelet activating factor (PAF) and partial inhibition by ketiprofen in calves, Vet. Res. 28 (1997) 489-502.
5: Bastos da Silva M., Gustin P., Herion F., David J.-L., Van De Weerdt M.L., Lekeux P., Effect of ketoprofen on PAF-induced bovine platelet aggregation, Vet. J. 155 (1998) 201-203.
6: Bernart A., Herbert J.-M., Salel V., Lespy L., Maffrand J.P., Protective effect of SR 27417, a novel PAF antagonist, on PAF or endotoxin-induced hypotension in the rat and the guinea-pig, J. Lipid. Mediators 51 (1992) 41-48.
7: Bernart A., Herbert J.-M., Effect of various drugs on adriamycin-enhanced venous thrombosis in the rat: importance of PAF, Thromb. Res. 75 (1994) 91-97.
8: Bondy G.S., Gentry P.A., Characterization of the normal bovine platelet aggregation response, Comp. Biochem. Physiol. C92 (1989) 67-72.
9: Born G.V.R., Quantitative investigations into the aggregation of blood platelets, J. Physiol. (Lond.) 162 (1962) 67.
10: Braquet P., Godfroid J.J., PAF-acether binding sites: 2 designers of specific antagonists, Trends Pharmacol. Sci. 7 (1986) 397-403.
11: Braquet P., Touqui L., Shen T.Y., Vargaftig, B.B., Perspectives in platelet-activating factor research, Pharmacol. Rev. 39 (1987) 97-145.
12: Casals-Stenzel J., Weber K.H., Triazolodiazepines: dissociation of their PAF (platelet-activating factor) antagonistc and CNS activity, Br. J. Pharmacol. 90 (1987) 139-146.
13: Chan W.P., Levy J.V., Effects of antiplatelet agents on platelet aggregation induced by platelet-activating factor (PAF) in human whole blood, Prostaglandins 42 (1991) 337-342.
14: Cheryk L.A., Hooper-Mcgrevy H.E., Gentry P.A., Alterations in bovine platelet function and acute phase proteins induced by Pasteurella haemolytica A₁, Can. J. Vet. Res. 62 (1998) 1-8.
15: Chignard M., Le Couedic J.P., Tencé M., Vargaftig B.B., Benveniste J., The role of platelet-activating factor in platelet aggregation, Nature (London) 279 (1979) 799-800.
16: Collins L.C., Roberts A.M., Effects of platelet-activating factor on arteriolar and venular tone in rat trachea, Microvasc. Res. 53 (1997) 63-72.
17: Foster A.P., Cunningham F.M., Andrews M.J., Lees P., A comparison of the action of platelet-activating factor (PAF) antagonists WEB 2170 and 2086 in the horse, J. Vet. Pharmacol. Ther. 16 (1993) 477-487.
18: Handley D.A., Development and therapeutic indications for PAF receptor antagonist, Drugs Future 13 (1988) 137-152.
19: Heath M.F., Evans R.J., Hayes L.J., Dextran-70 inhibits equine platelet aggregation induced by PAF but not by other agonists, Equine Vet. J. 30 (1998) 408-411.
20: Hellewell P.G., Williams T.J., Antagonism of PAF-induced oedema formation in rabbit skin: a comparison of different agonists, Br. J. Pharmacol. 97 (1989) 171.
21: Herbert J.M., Bernart A., Valette G., Gigo V., Lale A., Laplace M.C., Lespy L., Savi P., Maffrand J.P., Le Fur G., Biochemical and pharmacological activities of SR 27417, a highly potent, long acting platelet activating factor receptor antagonist, J. Pharmacol. Exp. Therapy 259 (1991) 44-51.
22: Herbert J.M., Valette G., Bernart A., Savi P., Maffrand J.P., Le Fur G., SR 27417, a highly potent, selective and long-acting antagonist of the PAF receptor, Drugs Future 17 (1992) 1011-1018.
23: Herbert J.M., Laplace M.C., Maffrand J.P., Bindind of [ $_{\_}$ H]SR 27417, a novel platelet-activating factor (PAF) receptor antagonist, to rabbit and human platelets and polymorphonuclear leukocytes, Biochem. Pharmacol. 45 (1993) 51-58.
24: Herbert J.M., Bernart A., Tibirica E., Effect of SR 27417, a novel PAF antagonist on antigen-induced hypotension in the rat, J. Lip. Mediators Cell Signal. 15 (1997) 115-123.
25: Imai T., Adachi M., Horikoshi S., Sugeta A., Idaira K., Takahashi T., Tanaka Y., Relation of platelet activating factor induced airway hyperresponsiveness to thromboxane A2 and neutrophil in dogs, Arerugi 42 (1993) 1563-1568.
26: Kenakin T.P., Pharmacological analysis of drug receptor interaction, Raven, New York, 1987, pp. 210-217.
27: Lekeux P., Gustin P., Desmecht D., Linden A., Thérapeutique des pathologies respiratoires aiguës des bovins, Ann. Méd. Vét. 135 (1991) 175-184.
28: Leroy P., Farnir F., Méthodes Statistiques en Médecine Vétérinaire, Départment de Génétique, Faculté de Médecine Vétérinaire-Université de Liège, Belgique, 1998, pp. 251-257.
29: Livio M., Vigano G., Morigi M., Ubiali A., Galbusera M., Remuzzi G., Rôle of platelet-activating factor in primary hemostasis, Am. J. Physiol. 254 (1988) 1218-1223.
30: Oyekan A.O., Ablordeppey S.Y., The mechanisms of the antiaggregatory effects of cryptolepine: the role of cyclic adenosine monophosphate and cellular Ca2+, Genet. Pharmacol. 24 (1993) 461-469.
31: Ponpidom M.M., Hwang S.B., Doebber T.W., Acton J.J., Alberts A.W., Biftu T., Brooker D.R., Bugianesi R.L. Chabala J.C., Gamble N.L., Graham D.W, Wu M.S., $\pm$ -trans-2-(3-Methoxy-5-methylsulfonyl-4-propoxyphenyl)-5-(3-,4,5-trimethoxyphenyl) tetra-hydrofuran (L-659-989), a novel, potent PAF receptor antagonist, Biochem. Biophys. Res. Comm. 150 (1988) 1213-1220.
32: Prescott S.M., Stafforini D.M., Zimmerman G.A., Mcintyre T.M., The natural history of PAF: from physiological regulator to pathological mediator, in: Proceedings 5th International Congress on Platelet-Activating Factor and Related Lipid Mediators, Berlin, 1995, p. 2.
33: Sagara H., Makino S., Fukuda T., PAF receptor antagonist in asthma therapy, Nippon Rinsho 54 (1996) 3056-3061.
34: Schorderet M., Pharmacologie des concepts fondamentaux aux applications thérapeutiques, Frison-Roché, Paris, Ed. Slaktine, 1988, pp. 3-19
35: Schumacher W.A., Steinbacher T.E., Heran C.L., Megill J.R., Durham S.K., Effects of antithrombotic drugs in a rat model of aspirin-insensitive arterial thrombosis, Thromb. Haem. 69 (1993) 509-514.
36: Soloviev A.I., Braquet P., Platelet-activating factor - A potent endogenous mediator responsible for coronary vasospasm, News Physiol. Sci. (NIPS) 7 (1992) 166-172.
37: Terashita Z.I., Imura Y., Nishikawa K., Inhibition by CV-3988 of the binding of [ $_{\_}$ H]-platelet activating factor (PAF) to the platelets, Biochem. Pharmacol. 34 (1985) 1491-1495.
38: Van De Weerdt M.-L., Desmecht D., Lekeux P., Effect of platelet-activating factor on bovine pulmonary function, Vet. Rec. 16 (1997) 168-172.
39: Vargaftig B.B., PAF a mediator in search of a disease, Clin. Rev. Allergy 12 (1994) 419-421.

Abstract